minoxidil/finasteride (CG2001) / Beijing Dayspring Pharmaceutical - LARVOL DELTA

O04 Pharmacological efficacy of low-dose oral minoxidil-finasteride combination for hair growth and stability in male androgenetic alopecia: a 12-month retrospective service evaluation. (PubMed, Br J Dermatol) - "Nonetheless, modest κ-values reinforce the necessity for objective imaging protocols or artificial intelligence-driven methods in future research. Prospective, controlled trials incorporating explicit safety monitoring and patient-reported outcomes are warranted to optimize dosing and validate long-term tolerability."

Journal • Retrospective data • Alopecia • Immunology

Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia (clinicaltrials.gov) - P3 | N=190 | Recruiting | Sponsor: EMS | Trial completion date: Sep 2025 ➔ Sep 2027 | Trial primary completion date: Apr 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

Updates in Treatment for Androgenetic Alopecia. (PubMed, Ann Dermatol) - "Topical minoxidil and oral finasteride are the most widely used treatments for AGA, addressing follicular miniaturization...Finasteride and dutasteride, both 5-α-reductase inhibitors that reduce DHT levels in hair follicles, are key androgen-targeting treatments, with newer formulations like topical and injectable options emerging alongside traditional oral forms...This review explores current and emerging treatments for AGA, addressing both androgen-targeted and non-androgen-targeted approaches with an emphasis on their mechanisms, efficacy, and safety. It ultimately aims to provide a comprehensive update on the latest advancements in AGA management."

Journal • Review • Alopecia • CNS Disorders • Immunology

Comparing minoxidil-finasteride mixed solution with minoxidil solution alone for male androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Front Med (Lausanne)) - "However, larger, standardized trials are needed to confirm long-term outcomes and optimize treatment protocols. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251054497, identifier CRD420251054497."

Journal • Retrospective data • Review • Alopecia • Immunology

Determination of 13 janus kinase inhibitors in anti-alopecia cosmetics by ultra-high performance liquid chromatography-tandem triple quadrupole composite linear ion trap mass spectrometry (PubMed, Se Pu) - "Anti-alopecia cosmetics are often found to contain illegal additions of prohibited drugs such as minoxidil， finasteride and other substances...An ultra-high performance liquid chromatography-multiple reaction monitoring-information dependent acquisition-enhanced production scanning （UHPLC-MRM-IDA-EPI） method was developed to determine 13 JAK inhibitors in anti-alopecia cosmetics， including baricitinib， tofacitinib， ritlecitinib， peficitinib， abrocitinib， upadacitinib， ivarmacitinib， fedratinib， filgotinib， ruxolitinib， momelotinib， pacritinib and bozitinib...Recoveries of the 13 JAK inhibitors ranged from 94.7% to 102.2% for the water-soluble matrix and from 92.4% to 99.2% for the cream matrix， with relative standard deviations （RSDs） ≤8.8%. This method is characterized by high efficiency， rapidity， accuracy， sensitivity and simplicity， making it a powerful tool for rapid risk screening and simultaneous quantitative analysis of JAK inhibitors in anti-alopecia cosmetics."

Journal • Alopecia • Immunology

Trichology in the Age of Misinformation: Bridging the Gap Between Evidence-Based Dermatology and Social Media Narratives (EADV 2025) - "Despite the availability of evidence-based treatments such as Minoxidil, Finasteride, Dutasteride, and Platelet-Rich Plasma (PRP), patients are frequently exposed to misinformation that promotes unverified, often ineffective remedies. Misinformation in trichology poses a growing challenge to evidence-based dermatology. However, it also offers an opportunity for dermatologists to reclaim the narrative through responsible use of social media and enhanced patient communication. By actively addressing myths, setting realistic expectations, and simplifying scientific information for digital platforms, dermatologists can build credibility, improve adherence, and protect patients from the pitfalls of pseudoscience."

Alopecia • Dermatology

Comparative Analysis of Platelet-Rich Plasma (PRP), Exosomes, and Minoxidil Therapy for Androgenic Alopecia (EADV 2025) - "Current treatments include minoxidil, finasteride, platelet-rich plasma (PRP), and novel regenerative approaches like exosome therapy. The results of this comparison highlight the strong promise of exosome therapy as a groundbreaking treatment for androgenic alopecia.. With its ability to induce rapid and robust follicular regeneration evidenced by near- complete vellus hair reduction, full anagen induction, and complete telogen suppression, exosome therapy demonstrates clear advantages over conventional treatments like PRP and minoxidil."

Alopecia • Immunology

Assessing safety and efficacy of a mixture of oral finasteride 1 mg, minoxidil 1 mg, and biotin 5 mg in treatment of androgenetic alopecia in males: a single-arm, before-after clinical trial (EADV 2025) - "Current treatments for AGA include minoxidil, finasteride, dutasteride, injections, microneedling, low-level laser therapy, and hair transplant. The oral combination of finasteride 1 mg, minoxidil 1 mg, and biotin 5 mg seems to be a safe and effective combination for treatment of AGA males with Norwood scale II-IV. The effectiveness seems to be mostly driven by objective increased duration of anagen phase. Larger controlled and randomized clinical trials in different settings and on different age and sex groups are needed to confirm results of this clinical trial."

Clinical • Aesthetic Medicine • Alopecia • Fatigue • Immunology • AR

Analysis of Hair Loss Severity and Treatment Approaches in 100 Male Patients with Androgenetic Alopecia (EADV 2025) - "Patients were categorized into the following groups: Stages 1–3: 51 patients, Stages 4–5: 31 patients, Stages 6–7: 18 patients Detailed medical history and prior treatments were recorded, including the use of finasteride, minoxidil, and local therapies (e.g., mesotherapy, platelet-rich plasma). Effective treatment for androgenetic alopecia is often initiated too late, which limits the success of hair transplantation. Early pharmacological intervention with finasteride and minoxidil can improve the overall condition of the scalp and increase the success rate of FUE procedures. Hair loss exceeding stage 6 on the Hamilton-Norwood scale presents challenges for successful transplantation due to limited donor site availability."

Clinical • Aesthetic Medicine • Alopecia • Immunology

Advances in Transdermal Delivery Systems for Treating Androgenetic Alopecia. (PubMed, Pharmaceutics) - "Traditional treatment options, including minoxidil, finasteride, and hair transplantation, have their limitations, such as skin irritation, systemic side effects, invasiveness, and high costs. It analyzes the underlying mechanisms that enhance drug penetration through hair follicles. Finally, this review presents a forward-looking perspective on the future use of TDDS in the management of AGA, aiming to provide insights and references for designing effective transdermal drug delivery systems for this condition."

Journal • Review • Aesthetic Medicine • Alopecia • Immunology • Transplantation

Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation. (PubMed, Aesthetic Plast Surg) - "Subsequently, a comprehensive analysis of the predominant product categories and ingredients currently available on the market was conducted, encompassing minoxidil, finasteride, plant extracts, growth factors, and peptides. By synthesizing extant research and delineating prospective research directions, this paper establishes an indispensable reference point for the research and development of cosmetics designed to promote hair growth and prevent hair loss.Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors   www.springer.com/00266 ."

Journal • Review • Alopecia • Gene Therapies • Immunology

Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia (clinicaltrials.gov) - P2 | N=110 | Recruiting | Sponsor: Beijing Dayspring Pharmaceutical Technology Co., Ltd

New P2 trial • Alopecia • Dermatology • Immunology

Phase I Clinical Trial of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia (clinicaltrials.gov) - P1 | N=44 | Completed | Sponsor: Beijing Dayspring Pharmaceutical Technology Co., Ltd

New P1 trial • Alopecia • Dermatology • Immunology